Scholar Rock Holding (SRRK) Current Deferred Revenue (2017 - 2021)
Scholar Rock Holding (SRRK) recorded quarterly Current Deferred Revenue of $33.2 million in Q4 2021, down 10.87% quarter-over-quarter from $37.2 million in Q3 2021, and up 76.41% on a YoY basis from $18.8 million in Q4 2020.
Scholar Rock Holding (SRRK) Current Deferred Revenue (2017 - 2021) Analysis & Trends
Scholar Rock Holding's Current Deferred Revenue history runs 5 years deep, the most recent figure standing at $33.2 million for Q4 2021.
- In Q4 2021, Current Deferred Revenue rose 76.41% year-over-year to $33.2 million; the TTM figure through Dec 2021 stood at $33.2 million (up 76.41% YoY), while the FY2021 annual figure was $33.2 million, up 76.41% from the prior year.
- Current Deferred Revenue was $33.2 million for Q4 2021 at Scholar Rock Holding, down from $37.2 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $47.3 million in Q1 2021 to a low of $228000.0 in Q4 2017.
- Historically, Current Deferred Revenue has averaged $24.5 million across 5 years, with a median of $20.6 million in 2019.
- The sharpest annual moves came in 2018 and 2020: Current Deferred Revenue surged 8763.6% in 2018, then slumped 35.84% in 2020.
- A 5-year view of Current Deferred Revenue shows it stood at $228000.0 in 2017, then soared by 8763.6% to $20.2 million in 2018, then advanced by 3.53% to $20.9 million in 2019, then declined by 10.07% to $18.8 million in 2020, then soared by 76.41% to $33.2 million in 2021.
- The last three Current Deferred Revenue figures came in at $33.2 million (Q4 2021), $37.2 million (Q3 2021), and $42.7 million (Q2 2021), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 33.19 Mn |
| Sep 30, 2021 | 37.24 Mn |
| Jun 30, 2021 | 42.71 Mn |
| Mar 31, 2021 | 47.30 Mn |
| Dec 31, 2020 | 18.82 Mn |
| Sep 30, 2020 | 16.71 Mn |
| Jun 30, 2020 | 20.36 Mn |
| Mar 31, 2020 | 16.27 Mn |
| Dec 31, 2019 | 20.92 Mn |
| Sep 30, 2019 | 20.25 Mn |
| Jun 30, 2019 | 23.52 Mn |
| Mar 31, 2019 | 25.36 Mn |
| Dec 31, 2018 | 20.21 Mn |
| Dec 31, 2017 | 228,000.00 |